Bacher v. Boehringer Ingelheim Pharmaceuticals, Inc.

CourtDistrict Court, D. Connecticut
DecidedJanuary 17, 2023
Docket3:22-cv-01432
StatusUnknown

This text of Bacher v. Boehringer Ingelheim Pharmaceuticals, Inc. (Bacher v. Boehringer Ingelheim Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bacher v. Boehringer Ingelheim Pharmaceuticals, Inc., (D. Conn. 2023).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT

BETH BACHER et al., Plaintiffs,

v. No. 3:22-cv-01432 (JAM)

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. et al., Defendants.

ORDER GRANTING MOTION TO REMAND

The Class Action Fairness Act (“CAFA”) generally allows for federal jurisdiction over cases that qualify as a “mass action.” As relevant here, a “mass action” includes “any civil action … in which monetary relief claims of 100 or more persons are proposed to be tried jointly on the ground that the plaintiffs’ claims involve common questions of law or fact.” 28 U.S.C. § 1332(d)(11)(B)(i) (emphasis added). The defendants invoked this “mass action” provision as grounds to remove this case and eight similar cases that the plaintiffs initially filed in Connecticut state court. The defendants filed their notices of removal after the plaintiffs filed a motion in state court to consolidate all nine of the cases. The defendants argue that by filing their motion to consolidate the plaintiffs proposed a joint trial of the claims of more than 100 persons. The plaintiffs do not agree. They have moved to remand, arguing that they proposed consolidation solely for the purpose of pre- trial case management and not for a joint trial. I conclude that the defendants have not carried their burden to show that there was a “mass action” to trigger federal jurisdiction under CAFA, because the defendants have not shown that the plaintiffs proposed a joint trial of their claims. Accordingly, I will grant the plaintiffs’ motion to remand to state court. BACKGROUND This action is one of nine separate lawsuits involving highly similar personal injury claims by a total of more than 800 plaintiffs against several companies that manufacture or distribute a pharmaceutical product known as Zantac. All nine of the actions were initially filed

during the Summer of 2022 in the Connecticut Superior Court for the Judicial District of Danbury, and each action includes somewhere between 80 to 99 plaintiffs. In the Fall of 2022, counsel for plaintiffs and for one of the defendants communicated with respect to the plaintiffs’ proposal to file a motion to consolidate the actions and for transfer of the actions to the specialized Complex Litigation Docket (“CLD”) of the Connecticut Superior Court.1 On October 21, 2022, defense counsel wrote the following email to plaintiffs’ counsel: Before I start making my calls, I want to make sure my notes are accurate. Plaintiffs want all cases consolidated in the same court and as far as CLD designation, would like to designate: 1) Hartford, 2) Stamford. If I have that right, I will start making calls today and hopefully get back to you early next week.2

Five days later, counsel for plaintiffs wrote: “My guys are anxious to file the consolidation motions/CLD application. Any progress on your end?”3 Defense counsel responded: “It appears all defendants are comfortable with recommending: 1) Hartford and 2) Stamford under CLD.”4 Plaintiffs’ counsel responded “Thanks,” and “We’ll prepare the consolidation motion and CLD application.”5 Several more days passed before defense counsel inquired of plaintiffs’ counsel: “Any update on Plaintiffs’ CLD application?”6 Plaintiffs’ counsel replied: “We’re working on the

1 Docs. #30-2, #30-3, #40-1; see also State of Connecticut Judicial Branch, Facts About the Connecticut Judicial Branch Complex Litigation Docket, https://www.jud.ct.gov/external/super/FACTS_092021.pdf (last accessed January 17, 2023) [https://perma.cc/VJ8A-GGME]. 2 Doc. #30-2 at 3. 3 Ibid. 4 Id. at 2. 5 Ibid. 6 Doc. #30-3 at 2. consolidation motions today. Our thought is to get everything consolidated and then file the CLD so we can do it with one application. I expect will have step one on file this week.”7 On that same day, the plaintiffs filed a motion in the Connecticut Superior Court for the Judicial District of Danbury to consolidate all nine actions.8 The motion stated that it was filed

“[p]ursuant to Conn. Prac. Book § 9-5” and set forth verbatim the following grounds: 1. These actions are all against the same Defendants. 2. All of the actions involve the same legal claims sounding in product liability related to the heartburn medication Zantac. 3. It is likely that issues raised in any one of the cases could impact the other cases. 4. Consolidating these actions will allow for the court to manage all of them in an orderly and efficient manner. 5. Plaintiffs are filing similar consolidation motions in each of the above-listed actions. 6. All Defendants consent to this proposed consolidation.9 There is no record that the state court acted on the motion to consolidate. Instead, on November 4, 2022, the chief administrative judge for the Connecticut Superior Court sua sponte issued an order conditionally ordering the transfer of the nine actions to the Complex Litigation Docket.10 But that transfer never happened because on November 10, 2022, the defendants filed notices of removal for all nine actions. The plaintiffs in turn have moved to remand all of the actions to the Connecticut Superior Court.

7 Ibid. Although it is not completely clear why the plaintiffs sought to consolidate the nine cases prior to transfer, “[p]ursuant to Connecticut General Statutes Sec. 52-259, there is a $335.00 fee for each case requested” for transfer to the CLD. See Facts About the Connecticut Judicial Branch Complex Litigation Docket, supra note 1, at 1. 8 Doc. #1-2 at 84–85; see also Doc. #1 at 5 (¶ 12). 9 Doc. #1-2 at 84–85. The defendants do not dispute that they consented to transfer to the CLD but dispute that they consented to the proposed consolidation. Doc. #40 at 8; Doc. #40-1 at 2–3 (¶¶ 9–10). 10 Doc. #30 at 2; Doc. #30-1 at 2. DISCUSSION CAFA “expanded the jurisdiction of the federal courts to allow class actions originally filed in state courts that conform to particular requirements to be removed to federal district courts.” Purdue Pharma L.P. v. Kentucky, 704 F.3d 208, 213 (2d Cir. 2013).11 “In general,

CAFA amended the diversity statute to confer federal jurisdiction over certain class actions where: (1) the proposed class contains at least 100 members (the ‘numerosity’ requirement); (2) minimal diversity exists between the parties, (i.e., where ‘any member of a class of plaintiffs is a citizen of a State different from any defendant’); and (3) the aggregate amount in controversy exceeds $5,000,000.” Ibid. (citing 28 U.S.C. § 1332(d)(2)–(6)). “CAFA’s reach, however, is limited in the first instance to actions that qualify as either a ‘class action’ or a ‘mass action.’” Ibid. (citing 28 U.S.C. § 1332(d)(1)–(2), (11), and 28 U.S.C. § 1453(b)). According to CAFA, “a mass action shall be deemed to be a class action removable” from state court to federal court for the same reasons that a defendant may remove a class action. 28 U.S.C. § 1332(d)(11)(A). Thus, “defendants in civil suits may remove ‘mass actions’ from

state to federal court.” See Mississippi ex rel. Hood v. AU Optronics Corp., 571 U.S. 161, 164 (2014). CAFA defines a “mass action” in relevant part to mean “‘any civil action … in which monetary relief claims of 100 or more persons are proposed to be tried jointly on the ground that the plaintiffs’ claims involve common questions of law or fact.” 28 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Abbott Laboratories v. Rhealyn Alexander
698 F.3d 568 (Seventh Circuit, 2012)
Purdue Pharma L.P. v. Commonwealth of Kentucky
704 F.3d 208 (Second Circuit, 2013)
Geoffrey Scimone v. Carnival Corporation
720 F.3d 876 (Eleventh Circuit, 2013)
Montefiore Medical Center v. Teamsters Local 272
642 F.3d 321 (Second Circuit, 2011)
Dawn Atwell v. Boston Scientific Corporation
740 F.3d 1160 (Eighth Circuit, 2013)
Mississippi Ex Rel. Hood v. AU Optronics Corp.
134 S. Ct. 736 (Supreme Court, 2014)
Teague v. Johnson & Johnson
749 F.3d 879 (Tenth Circuit, 2014)
Margalit Corber v. Xanodyne Pharmaceuticals, Inc.
771 F.3d 1218 (Ninth Circuit, 2014)
Groth v. Redmond
194 A.2d 531 (Connecticut Superior Court, 1962)
Warren Lester v. Exxon Mobil Corporation, e
879 F.3d 582 (Fifth Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Bacher v. Boehringer Ingelheim Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/bacher-v-boehringer-ingelheim-pharmaceuticals-inc-ctd-2023.